Pan PPAR agonists are being studied for many different conditions such suppressing inflammation and increasing lipid oxidation (188), protecting against metabolic disorders and fibrosis (189), and even angiogenesis in ischemic mice (190). Here, PPARA is linked to metabolic disease.